The United Kingdom is on EDA's reference-country list, and the most valuable thing that buys is not a shorter review. It is that a site in a reference country is waived from EDA's on-site inspection altogether — the authority reviews the certificate and does not come.
EDA's reference-country list for medicines runs to twenty-four names, and it is built country by country with no European Union bloc entry at all. Ireland, Germany and France are each listed individually, and so is the United Kingdom, third on the list. Brexit is structurally irrelevant here: there was never a bloc entry for Britain to fall out of.
That list drives the reliance pathways. The verification route needs approval by at least two of those authorities, or one plus World Health Organization prequalification. The abridged route needs one. Both require the dossier to be the same one you filed with the reference agency, an unredacted assessment report, and a certificate of pharmaceutical product.
EDA's registration guideline sets a separate fast-track ladder by origin of approval. Track A — approval by both the US FDA and the EMA — is one month from receipt of a complete dossier. Track B — one of those two — is two months. Track C runs three to six months depending on origin. A UK authorisation puts you on the reference list and into the reliance pathways; it does not, on the published wording, put you on Track A or B.
This is the same shape we found in Saudi Arabia: one list that admits the MHRA, another that does not. It is worth establishing in writing which track your file will run on before anyone quotes you a timeline.
A warning about the timelines you will be quoted. The figures circulating widely — thirty days for a dual-agency abridged file, sixty for a single-agency one — come from version 3 of EDA's reliance guideline, which version 4 superseded in August 2024 without carrying them forward. Anyone quoting them today is citing a withdrawn document. The live clock sits in an appendix to the registration guideline that we could not retrieve, and we would rather tell you that than repeat a number from a version EDA has replaced.
EDA's own words: imported medicinal products from reference countries are "waived from EDA on-site inspection as a prerequisite for approving the manufacturing site. Whereas EDA shall only review the site valid GMP certificate"
A waiver is available for innovator products and for imported generics already approved by one of the reference authorities
Recognised through WHO prequalification of the API, or a European certificate of suitability
EDA will rely on stability data generated in the country of origin rather than requiring it regenerated for Zone IV conditions
Defined by FDA and EMA approval. A UK authorisation is not named
From EDA's reliance practices guideline, version 4, issued and effective 11 August 2024. Sites outside the reference countries need a valid inspection accreditation report from a stringent authority or a certifying international body instead. Note that Egypt is not a member of the international inspection cooperation scheme — it applied for pre-accession in September 2023 — so this waiver is EDA's own policy rather than a consequence of mutual membership.
A human pharmaceutical marketing authorisation in Egypt runs ten years, against five in Saudi Arabia, five in the UAE and five for South African establishment licences. Re-registration is applied for during the last year of validity.
And if you miss it, the consequence is unusually forgiving: a product holding preliminary approval to proceed with re-registration is granted a grace period of up to four years from the expiry date. There is also a mid-term obligation that is easy to overlook — a safety, quality and efficacy report during the last three months of the fifth year.
| Re-registration stage | Working days |
|---|---|
| Initial screening | 20 |
| Technical evaluation | 60 |
| First requirement review | 30 |
| Second requirement review | 30 |
| Presentation to committee | 30 |
| Your window to fulfil requirements | 120 days, in up to two intervals |
| Appeal, from issuance of the decision | 60 |
From EDA's re-registration guideline, version 7, issued 30 December 2025 and effective 1 January 2026 — the clearest published clock we found for any Egyptian medicines process.
EDA's registration guideline permits applications from licensed local pharmaceutical factories, factories under construction, toll manufacturing companies, scientific offices and authorised import companies. For an imported product the file needs a valid and legalised agency agreement or authorisation letter between the licence holder and the applicant, plus a legalised certificate of pharmaceutical product.
A sourced negative worth having, because the opposite is widely assumed: there is no requirement to manufacture or toll-manufacture in Egypt. Toll manufacturing is an option with its own slot limits, not a condition of registration. What does exist is policy pressure rather than law — EDA's published strategy to 2030 targets localising the top fifty imported active ingredients, about seventy-eight per cent of API imports by value, and notes that local production already covers around ninety-one per cent of the market.
We could not establish whether the applicant must be an Egyptian-incorporated entity. No instrument says so expressly. In practice the company profile with EDA and the legalised agency agreement make local presence operationally necessary. We treat that as unresolved rather than asserting either answer.
Pricing runs as a separate process alongside registration, and approval must be obtained before registration completes. Products manufactured locally for export only, or for export and tender only, are exempt from pricing altogether. Those facts are from EDA's own guideline.
Beyond them, the published record thins sharply. The governing instrument is a ministerial decree of 2012, and neither its text nor its annexed list of reference countries is retrievable from any official Egyptian publication we could reach — the relevant EDA register pages refuse automated access. So the single question a UK company asks about Egyptian pricing, whether Britain is in the basket, we cannot answer. We are not going to answer it from a law firm's summary.
| Pricing service | Fee, EGP |
|---|---|
| New pricing submission | 5,000 |
| Price increase under the current criteria | 7,000 |
| Pricing alongside a variation | 2,000 |
| Price movement under the former criteria | 3,000 |
| Price decrease | 1,000 |
From an EDA pricing-mechanism document. Two timing rules come with them: a company may not apply for a price increase within one year of its previous pricing under the current criteria, while a decrease may be requested at any time and takes effect within three months of approval. Registration fees are published only as amounts embedded in the prose of one dossier guideline — EGP 1,000 to file a registration request, EGP 20,000 for a scientific office permission letter for imported products — and there is no published tariff by product type, no variation fee and no inspection fee amount.
Through late 2026 the Egyptian trade press has reported an overhaul: a reference basket cut from thirty-five countries to fifteen with a regional tilt, imported products priced at the lowest reference price less a further margin, locally manufactured products priced at a fraction of the imported equivalent, and a currency band below which prices do not move. We can find no decree number, no date and no EDA announcement. The chairman said in September 2026 that it would issue "within days".
If that reporting is right, the direction is away from Britain rather than towards it. We will publish the mechanics the day there is an instrument to cite, and not before.
The Department for Business and Trade maintains a public register of trade barriers. Egypt carried one for pharmaceuticals: UK businesses faced "significant delays when registering pharmaceutical products". It was reported in November 2019.
It is now marked resolved, in March 2025 — with the resolution attributed to regulatory capacity-building between NICE, the MHRA, the Department of Health and Social Care and the Egyptian authorities, and registration timelines described as having moved from years down to months.
Why we point you at it. It is a verifiable, dated, British-government statement about this exact market and this exact problem, and almost nobody selling Egyptian market access mentions it. If your board's impression of Egypt was formed before 2025, that record is the cheapest way to update it — and it is also the reason to treat pre-2025 advice about Egyptian registration timelines as stale.
The UK–Egypt Association Agreement, signed in December 2020, covers goods, services, sanitary measures, intellectual property and government procurement. It contains no pharmaceutical or conformity-assessment provision. The regulatory relationship here runs through that capacity-building work, not through the trade agreement.
The same law that created EDA created a unified procurement authority for the public health sector. On law-firm authority it is the exclusive purchaser of pharmaceutical products and medical equipment for all governmental and public entities, takes a fee of up to seven per cent of procurement value, and public bodies may not buy directly except in Cabinet-approved emergencies. Supplier registration with it appears to be separate from EDA product registration.
We could not confirm any of that from the authority itself. Its website refused every request we made, on the root and on every subpage. So the mandate, the exclusivity, the fee and the supplier registration requirements are reported here as what they are: assertions by Egyptian counsel that we have not been able to verify against the source.
What is better established is the procurement preference: Egypt's public contracting law gives a price preference of fifteen per cent to bidders supplying products that meet a minimum local-content percentage. The article number we could not obtain.
Egypt floated the pound in March 2024. The International Monetary Fund's March 2026 report records that there was no introduction or intensification of exchange restrictions or multiple currency practices inconsistent with Article VIII, and no capital flow management measures introduced in 2025, that the spread with parallel market measures remained closed with no foreign exchange backlogs, and that the central bank refrained from direct intervention through 2025. Reserves stood at 59.2 billion dollars at December 2025.
Two honest qualifications. The Fund's earlier report notes anecdotal evidence of some difficulty obtaining currency for current transactions even while market participants raised no significant issues. And every currency finding on this page comes from the Fund alone — the Central Bank of Egypt refuses automated access, so we have not read a single central bank circular directly. No priority foreign-exchange allocation for medicines appears anywhere in the accessible record.
Your own government's export guidance for Egypt advises secure payment terms, citing average dispute resolution of 1,010 days at around 26% of the claim value. That is a contract-drafting point rather than a currency one, and it is worth more attention than the exchange rate.
The 2012 pricing decree and its annexed country list are not retrievable from any official Egyptian source we could reach. No source of any kind that we found names the basket members.
The master timetable sits in an appendix to the registration guideline that did not render. The widely quoted thirty and sixty day figures belong to a withdrawn version.
EDA publishes an Arabic service catalogue with the right rows — including foreign factory inspection priced by continent — and no visible amounts. Medicine fees appear only as figures embedded in guideline prose.
Its website refused every request. Exclusivity, the seven per cent fee and supplier registration rest on Egyptian counsel, not on the source.
Announced by the chairman, reported in detail by the trade press, and traceable to no decree number or date as at the day we checked.
Studies must be run at EDA-licensed centres. The list of them is not published, and neither are the rules for licensing one.
Three of the four Egyptian official domains this page needed refuse automated access. Everything stated as fact above was read from an EDA document or an IMF or gov.uk publication; everything else is marked.
Egypt is the only market on this site that names the UK for both. The device page covers the separate instrument for devices marketed in Great Britain, requiring ISO 13485 plus UKCA certificates — a genuinely unusual position that no other regulator here matches. Two product types, one regulator, and Britain named in each.
The medical devices page for Egypt → · What an MHRA approval is worth in all six markets →
A hosted inspection is a fortnight of your quality team and a fee priced by continent. Send us the product and we will tell you whether your site qualifies for the waiver, which track your file runs on, and what the pricing exposure looks like once there is a decree to read.
Or reach us directly — mail@bcabusiness.co.uk · +44 7342 901002 · WhatsApp
Re-checked quarterly, and immediately when the new pricing decree issues — which will change the pricing section of this page substantially and may change whether Britain is in the basket at all. Biological and innovative products are registered by a different EDA administration under its own guideline, which this page does not cover.